Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MLYS Mineralys Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: MLYS
Price (delayed)
$15.35
Market cap
$1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.73
Enterprise value
$835.43M
We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone
Highlights
The company's quick ratio has surged by 89% QoQ and by 45% YoY
MLYS's equity has surged by 79% since the previous quarter and by 4.1% year-on-year
The net income has dropped by 108% year-on-year and by 6% since the previous quarter
The EPS has dropped by 69% year-on-year
Key stats
What are the main financial stats of MLYS
Market
Valuations
Earnings
Shares outstanding
65.18M
Market cap
$1B
Enterprise value
$835.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$201.49M
Net income
-$188.51M
EBIT
-$188.51M
EBITDA
-$188.46M
Free cash flow
-$192.7M
Per share
Balance sheet
Liquidity
EPS
-$3.73
EPS diluted
-$3.73
Free cash flow per share
-$3.62
Book value per share
$6.85
Revenue per share
$0
TBVPS
$6.68
Total assets
$354.94M
Total liabilities
$13.39M
Debt
$0
Equity
$341.56M
Working capital
$341.12M
Debt to equity
0
Current ratio
26.48
Quick ratio
25.63
Net debt/EBITDA
0.88
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65.7%
Return on equity
-71.1%
Return on invested capital
-122.5%
Return on capital employed
-55.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLYS stock price
How has the Mineralys Therapeutics stock price performed over time
Intraday
-0.07%
1 week
4.78%
1 month
13.7%
1 year
16.73%
YTD
24.7%
QTD
-3.34%
Financial performance
How have Mineralys Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$201.49M
Net income
-$188.51M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 108% year-on-year and by 6% since the previous quarter
The company's operating income has shrunk by 92% YoY and by 4.7% QoQ
Price vs fundamentals
How does MLYS's price correlate with its fundamentals
Growth
What is Mineralys Therapeutics's growth rate over time
Valuation
What is Mineralys Therapeutics stock price valuation
P/E
N/A
P/B
2.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 69% year-on-year
MLYS's equity has surged by 79% since the previous quarter and by 4.1% year-on-year
The stock's P/B is 10% less than its last 4 quarters average of 2.5
Efficiency
How efficient is Mineralys Therapeutics business performance
MLYS's ROIC has plunged by 167% YoY and by 17% from the previous quarter
MLYS's ROE has shrunk by 119% YoY and by 4.6% QoQ
The ROA has dropped by 111% year-on-year and by 5% since the previous quarter
Dividends
What is MLYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLYS.
Financial health
How did Mineralys Therapeutics financials performed over time
The company's quick ratio has surged by 89% QoQ and by 45% YoY
The current ratio has soared by 89% from the previous quarter and by 47% YoY
Mineralys Therapeutics's debt is 100% lower than its equity
MLYS's equity has surged by 79% since the previous quarter and by 4.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.